Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Stefan Kubicka(Medizinische Hochschule Hannover), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Björn Jagdt(Institut de Cancérologie de l'Ouest), Bohuslav Melichar(Palacký University Olomouc), Jos Janssens(Hospital Clínico San Carlos), Hannah Weiss(NYU Langone Health), R. Ristamäki(Reutlingen University), Dirk Arnold(Asklepios Klinik Altona), Christoph Tinchon(LKH Hochsteiermark), Marc De Man(Reutlingen University), Irmarie Reyes‐Rivera(Baylor College of Medicine), Jana Prausová(University Hospital in Motol), Roger von Moos(Kantonsspital Graubünden), H. Samonigg, P Balcke(University of Vienna), Jaafar Bennouna(Hôpital Foch), Matthias Schmid(Zimmer Biomet (Netherlands)), Peter Krippl, Horst Oexle, J. Thaler(Medical University of Vienna), Richard Greil(Paracelsus Medical University), Kristiina Ojamaa(Roche (Switzerland)), Fahimeh Andersen, G Demolin(Reutlingen University), Kell Østerlind(Zealand University Hospital), Martina Makrutzki(Roche (Switzerland)), W. Eisterer, Pia Österlund(University of Helsinki), Tapio Salminen(Tampere University Hospital), O. Bouché(Reutlingen University), Thomas Müller(Johns Hopkins University), Marc Polus, Nina Keldsen(University of Freiburg), Michael Fridrik, Javier Sastre(Hospital Clínico San Carlos), Thierry André(Inserm), Brita B. Jensen, A. Kretschmer, Eric Van Cutsem(Universitair Ziekenhuis Leuven), Pavel Vítek(Czech Academy of Sciences, Global Change Research Institute), Felix Keil(Hanusch Hospital), B. Benedicic(Institut de Cancérologie de l'Ouest), B. Benczikova(Institut de Cancérologie de l'Ouest), Janine Arts(Sanquin), Johannes Andel(Engineering Software Steyr (Austria)), Kirsten Vistisen(University of Copenhagen), Agnes Mägi(University of Tartu), Anneli Elme(North Estonia Medical Centre), Martin Pecherstorfer(Wilhelminen Hospital), Méher Ben Abdelghani(Université Paris Cité)
Cited by 104
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k